An observational study in Lower Extremity Acute Limb Ischemia and LE ALI, sponsored by Penumbra Inc.. Recruiting at 45 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Penumbra Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Ischemia with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Ischemia · United States.
Among the 155 studies in Ischemia with a site in United States, this one is the 16th largest by planned enrollment of the 53 observational ones that give a count, is one of 5 that started in 2025, is one of 53 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 150th registered.
545 studies on the registry are indexed under Ischemia; 71 are open to participants now.
Browse Ischemia studies →20 of the 155 studies in Ischemia with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 40+
Baylor Research Institute · Sites in United States
Ages 18+
Samaritan Biologics · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
Raul Nogueira · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 36 · Phase 3 13 · Phase 4 7
First in 1993; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 176 across 166 observational studies indexed under Ischemia.
Median enrollment 60 across the 100 interventional studies, 191 across the 53 observational. Of the 109 that completed or were terminated, 38 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 155 have an industry lead sponsor. The 10 most frequent:
Penumbra Inc. is the lead sponsor of 33 studies on the registry; 4 are open to participants now.
Penumbra Inc. has 4 studies filed under Ischemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Ischemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06271577AliveCorSmartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II | 2026-12 |
| NCT06437028Samaritan BiologicsEvaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers. | 2027-03 |
| NCT00762333UConn HealthCirculating Markers for Ischemic Heart Disease | 2027-03 |
| NCT06896903Baylor Research InstituteAnalysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 155 studies in Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI).
Patients that present with LE ALI who are eligible for mechanical thrombectomy using the Indigo Aspiration System
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Indigo Aspiration System
Device: Indigo Aspiration System
Mechanical aspiration thrombectomy with the Indigo Aspiration System.
Target Limb Salvage Rate
Time frame: 30 Days Post-Procedure
Technical Success
Technical success by treated segment defined as Thromboaspiration in Peripheral Ischemia (TIPI) 2/3 flow immediately post procedure by physician visual assessment of intraprocedural angiography
Time frame: Immediate Post Procedure
Primary Patency at 30 Days
Time frame: 30 Days Post-Procedure
Rates of Device-related Major Bleeding
Time frame: Procedure, 30 Days, and 180 Days Post-Procedure
Rates of Device-related Distal Embolization
Time frame: During Procedure
Rates of Device-related Serious Adverse Events (SAE)
Time frame: Procedure, 30 Days, and 180 Days Post-Procedure
Mortality
All cause mortality at 30 and 180 days
Time frame: 30 Days and 180 Days Post-Procedure
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.
Of 70 observational studies under Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's planned 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.